The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Subscribe To Our Newsletter & Stay Updated
